Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 15c, Revenues Miss

May 10, 2021 7:35 AM EDT
Get Alerts ITCI Hot Sheet
Price: $43.45 +0.63%

EPS Growth %: +11.0%

Today's EPS Names:
More
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.65), $0.15 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $15.9 million versus the consensus estimate of $16.5 million.

“The acceptance of our sNDAs by the FDA is an important step towards a potential new treatment option for patients living with bipolar depression, a condition with a limited number of approved treatments. While preparing for this significant opportunity, our team will continue to execute on our commercial objectives for CAPLYTA and advance our robust pipeline,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Earnings, Management Comments

Related Entities

The Children's Investment Fund (TCI), Earnings, FDA